Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers

• Published in: PloS one Vol. 10; no. 3; p. e0121872
• Main Authors: Dodbiba, Lorin, Teichman, Jennifer, Fleet, Andrew, Thai, Henry, Starmans, Maud H W, Navab, Roya, Chen, Zhuo, Girgis, Hala, Eng, Lawson, Espin-Garcia, Osvaldo, Shen, Xiaowei, Bandarchi, Bizhan, Schwock, Joerg, Tsao, Ming-Sound, El-Zimaity, Hala, Der, Sandy D, Xu, Wei, Bristow, Robert G, Darling, Gail E, Boutros, Paul C, Ailles, Laurie E, Liu, Geoffrey
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 31.03.2015; Public Library of Science (PLoS)
• Subjects: Adenocarcinoma; Analysis; Animal models; Animals; Biophysics; Breast cancer; Chemotherapy; DNA methylation; Drug testing; Epidermal growth factor receptors; ErbB-2 protein; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophagogastric Junction - pathology; Esophagus; Evolution & development; Experiments; Gene expression; Health aspects; Health care networks; Hospitals; Humans; Informatics; Lung cancer; Markers; Medical prognosis; Medical research; Medical screening; Mice; Mice, Inbred NOD; Mice, SCID; Morbidity; mRNA; Oncology; p53 Protein; Pathology; Patients; Pharmacology; Proteins; RNA; Sensitivity; Sensitivity analysis; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stroma; Thoracic surgery; Tumor proteins; Tumors; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation; Canada; United States > US

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53...